Inventiva (NASDAQ:IVA) Shares Gap Up - Should You Buy?

Key Points

• Inventiva's stock price gapped up during pre-market trading, opening at $6.17, an increase from the previous close of $5.91, but later traded at $6.06 with nearly 9,000 shares exchanged.
• A number of analysts have given Inventiva positive ratings, with HC Wainwright issuing a "buy" rating and a $20.00 price target, while Piper Sandler set an "overweight" rating with a target of $26.00.
• Institutional investors now own 19.06% of Inventiva shares, with Wealth Enhancement Advisory Services LLC increasing its stake by 54.5% in the latest quarter.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s share price gapped up before the market opened on Thursday . The stock had previously closed at $5.91, but opened at $6.17. Inventiva shares last traded at $6.06, with a volume of 8,927 shares traded.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright assumed coverage on Inventiva in a research note on Wednesday, September 3rd. They issued a "buy" rating and a $20.00 price objective for the company. Piper Sandler began coverage on Inventiva in a report on Wednesday, August 27th. They set an "overweight" rating and a $26.00 target price on the stock. Canaccord Genuity Group reiterated a "buy" rating and issued a $20.00 target price on shares of Inventiva in a research report on Tuesday. Finally, Guggenheim lifted their target price on Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Inventiva presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.57.

Inventiva Stock Performance

The company has a fifty day simple moving average of $4.77 and a two-hundred day simple moving average of $3.80.

Institutional Trading of Inventiva

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC grew its position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,558 shares of the company's stock after buying an additional 5,843 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 19.06% of the company's stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.